Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FOCL
FocalTherics
$4.20
-2.8%		$4.76
$1.75
▼
$6.40
$157.62M-0.0684,476 shs52,914 shs
Outset Medical, Inc. stock logo
OM
Outset Medical
$3.96
+5.6%		$3.94
$2.84
▼
$16.16
$70.49M2181,702 shs483,708 shs
Profound Medical stock logo
PROF
Profound Medical
$5.84
-0.2%		$6.67
$4.80
▼
$8.95
$213.52M0.75136,748 shs67,835 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$2.16
-2.7%		$2.71
$0.80
▼
$3.44
$169.16M1.191.26 million shs1.26 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FOCL
FocalTherics
-2.78%-10.83%-0.47%-18.92%+419,999,900.00%
Outset Medical, Inc. stock logo
OM
Outset Medical
+5.60%+29.84%+7.90%-16.10%-71.75%
Profound Medical stock logo
PROF
Profound Medical
-0.17%+1.39%-14.37%-14.24%+18.22%
Neuronetics, Inc. stock logo
STIM
Neuronetics
-2.70%-21.17%-22.02%+53.19%-20.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FOCL
FocalTherics
$4.20
-2.8%		$4.76
$1.75
▼
$6.40
$157.62M-0.0684,476 shs52,914 shs
Outset Medical, Inc. stock logo
OM
Outset Medical
$3.96
+5.6%		$3.94
$2.84
▼
$16.16
$70.49M2181,702 shs483,708 shs
Profound Medical stock logo
PROF
Profound Medical
$5.84
-0.2%		$6.67
$4.80
▼
$8.95
$213.52M0.75136,748 shs67,835 shs
Neuronetics, Inc. stock logo
STIM
Neuronetics
$2.16
-2.7%		$2.71
$0.80
▼
$3.44
$169.16M1.191.26 million shs1.26 million shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FOCL
FocalTherics
-2.78%-10.83%-0.47%-18.92%+419,999,900.00%
Outset Medical, Inc. stock logo
OM
Outset Medical
+5.60%+29.84%+7.90%-16.10%-71.75%
Profound Medical stock logo
PROF
Profound Medical
-0.17%+1.39%-14.37%-14.24%+18.22%
Neuronetics, Inc. stock logo
STIM
Neuronetics
-2.70%-21.17%-22.02%+53.19%-20.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
FOCL
FocalTherics
2.40
Hold$7.7584.52% Upside
Outset Medical, Inc. stock logo
OM
Outset Medical
2.40
Hold$10.00152.53% Upside
Profound Medical stock logo
PROF
Profound Medical
2.67
Moderate Buy$11.5096.92% Upside
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.60
Moderate Buy$4.67116.05% Upside

Current Analyst Ratings Breakdown

Latest OM, PROF, STIM, and FOCL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2026
Neuronetics, Inc. stock logo
STIM
Neuronetics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$6.00
9/14/2026
Neuronetics, Inc. stock logo
STIM
Neuronetics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/11/2026
Neuronetics, Inc. stock logo
STIM
Neuronetics
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
9/11/2026
Neuronetics, Inc. stock logo
STIM
Neuronetics
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$5.00
9/9/2026
Neuronetics, Inc. stock logo
STIM
Neuronetics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$6.00
8/25/2026
FOCL
FocalTherics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
8/21/2026
Outset Medical, Inc. stock logo
OM
Outset Medical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/17/2026
FOCL
FocalTherics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/14/2026
FOCL
FocalTherics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$4.00
8/12/2026
Profound Medical stock logo
PROF
Profound Medical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/11/2026
Neuronetics, Inc. stock logo
STIM
Neuronetics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$5.00 ➝ $6.00
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
FOCL
FocalTherics
$79.31M1.99N/AN/A$0.52 per share8.08
Outset Medical, Inc. stock logo
OM
Outset Medical
$117.80M0.63N/AN/A$6.99 per share0.57
Profound Medical stock logo
PROF
Profound Medical
$19.09M11.19N/AN/A$1.83 per share3.19
Neuronetics, Inc. stock logo
STIM
Neuronetics
$155.10M1.06N/AN/A$0.38 per share5.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
FOCL
FocalTherics
-$29.25M-$1.03N/AN/AN/A-56.26%-248.00%-44.69%N/A
Outset Medical, Inc. stock logo
OM
Outset Medical
-$81.65M-$4.09N/AN/AN/A-63.06%-61.67%-28.25%11/9/2026 (Estimated)
Profound Medical stock logo
PROF
Profound Medical
-$42.57M-$0.98N/AN/AN/A-171.57%-63.03%-51.24%11/12/2026 (Estimated)
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$39M-$0.44N/AN/AN/A-19.62%-125.11%-22.15%11/3/2026 (Estimated)

Latest OM, PROF, STIM, and FOCL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
FOCL
FocalTherics
-$0.20-$0.39-$0.19-$0.39N/A$13.20 million
8/11/2026Q2 2026
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.1230-$0.05+$0.0730-$0.05$40.17 million$41.57 million
8/6/2026Q2 2026
Outset Medical, Inc. stock logo
OM
Outset Medical
-$0.7167-$0.80-$0.0833-$0.97$28.97 million$31.64 million
8/6/2026Q2 2026
Profound Medical stock logo
PROF
Profound Medical
-$0.22-$0.26-$0.04$0.26$4.75 million$2.48 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
FOCL
FocalTherics
N/AN/AN/AN/AN/A
Outset Medical, Inc. stock logo
OM
Outset Medical
N/AN/AN/AN/AN/A
Profound Medical stock logo
PROF
Profound Medical
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
FOCL
FocalTherics
1.79
1.60
1.38
Outset Medical, Inc. stock logo
OM
Outset Medical
1.03
5.19
4.11
Profound Medical stock logo
PROF
Profound Medical
N/A
6.46
5.31
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.84
1.88
1.69

Institutional Ownership

CompanyInstitutional Ownership
FOCL
FocalTherics
62.74%
Outset Medical, Inc. stock logo
OM
Outset Medical
N/A
Profound Medical stock logo
PROF
Profound Medical
47.86%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%

Insider Ownership

CompanyInsider Ownership
FOCL
FocalTherics
10.10%
Outset Medical, Inc. stock logo
OM
Outset Medical
2.50%
Profound Medical stock logo
PROF
Profound Medical
1.52%
Neuronetics, Inc. stock logo
STIM
Neuronetics
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
FOCL
FocalTherics
23037.53 million33.74 millionN/A
Outset Medical, Inc. stock logo
OM
Outset Medical
31018.80 million18.33 millionNot Optionable
Profound Medical stock logo
PROF
Profound Medical
16236.56 million36.01 millionOptionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
65876.20 million69.80 millionOptionable

Recent News About These Companies

Neuronetics stock holds after August 11 earnings beat
September 19, 2026  |  ad-hoc-news.deA
BTIG Research Reiterates Buy Rating for Neuronetics (NASDAQ:STIM)
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-btig-research-reiterates-buy-rating-for-neuronetics-nasdaq-stim-2026-09-17/
B Riley Securities initiates coverage of Neuronetics at buy
September 12, 2026  |  msn.comhttps://www.msn.com/en-us/money/economy/b-riley-securities-initiates-coverage-of-neuronetics-at-buy/ar-AA2c4hDW
B. Riley Initiates Neuronetics at Buy With $5 Price Target
September 11, 2026  |  marketscreener.comM
Neuronetics (NASDAQ:STIM) Now Covered by B. Riley Financial
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-neuronetics-nasdaq-stim-now-covered-by-b-riley-financial-2026-09-11/
Neuronetics, Inc. (NASDAQ:STIM) Receives Average Recommendation of "Moderate Buy" from Brokerages
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-neuronetics-inc-nasdaq-stim-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-09-11/
BTIG Research Reaffirms "Buy" Rating for Neuronetics (NASDAQ:STIM)
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-btig-research-reaffirms-buy-rating-for-neuronetics-nasdaq-stim-2026-09-09/
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357668/0/en/neurostar-advances-practice-innovation-with-first-ever-tms-integration-with-an-ehr-emr-system.html
BlackRock Inc. Invests $776,000 in Neuronetics, Inc. $STIM
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-invests-776000-in-neuronetics-inc-stim-2026-09-07/
Neuronetics (STIM) Q2 2026 Earnings Call Transcript
August 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/neuronetics-stim-q2-2026-earnings-154322384.html
Neuronetics (NASDAQ:STIM) Major Shareholder Acquires 14,000 Shares of Stock
August 18, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-stim-insider-buying-and-selling-2026-08-18/
Neuronetics, Inc. (STIM) Q2 FY2026 earnings call transcript
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/STIM/earnings/STIM-Q2-2026-earnings_call-660691.html
Neuronetics Inc (STIM) (Q2 2026) Earnings Call Highlights: Revenue Growth and Margin Expansion ...
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/neuronetics-inc-stim-q2-2026-210214027.html
Neuronetics: Q2 Earnings Snapshot
August 11, 2026  |  wtop.comW
Neuronetics Reports Second Quarter 2026 Financial and Operating Results
August 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/neuronetics-reports-second-quarter-2026-financial-and-operating-results-1036440611
Neuronetics, Inc. (STIM) Q2 2026 Earnings Call Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934722-neuronetics-inc-stim-q2-2026-earnings-call-transcript
Neuronetics narrows Q2 loss as Greenbrook growth drives 9% revenue increase
August 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/economy/neuronetics-narrows-q2-loss-as-greenbrook-growth-drives-9-revenue-increase/ar-AA29RRR5
Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates
August 11, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2972561/neuronetics-stim-reports-q2-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2972561
Neuronetics Reports Second Quarter 2026 Results, Highlights Revenue Growth and Improved Adjusted EBITDA
August 11, 2026  |  quiverquant.comQ
Malvern’s Neuronetics reaches deal with shareholder who pushed to break up company
August 5, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/malvern-s-neuronetics-reaches-deal-with-shareholder-who-pushed-to-break-up-company/ar-AA29olDT
Neuronetics and Jorey Chernett Announce Shared Vision
August 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337435/0/en/neuronetics-and-jorey-chernett-announce-shared-vision.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Gold-colored concept electric vehicle with a smooth, minimalist body parked outdoors near a building and tree.
Ride-Share Reckoning: Tesla Drives Into Uber's Lane
By Jeffrey Neal Johnson | September 7, 2026
Autonomous military drone with AV-style logo on the nose sitting on a runway, representing AeroVironment and the defense drone industry.
AeroVironment's Record Backlog and Earnings Beat Fuel Recovery Case
By Thomas Hughes | September 10, 2026
Stacks of US currency and an official document sit on a desk in a government chamber.
3 Stocks to Buy and Hold for Higher Interest Rates
By Thomas Hughes | September 9, 2026

FocalTherics NASDAQ:FOCL

$4.20 -0.12 (-2.78%)
As of 10/2/2026 04:00 PM Eastern

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.

Outset Medical stock logo

Outset Medical NASDAQ:OM

$3.96 +0.21 (+5.60%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$4.00 +0.04 (+1.14%)
As of 10/2/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Profound Medical stock logo

Profound Medical NASDAQ:PROF

$5.84 -0.01 (-0.17%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$5.84 +0.00 (+0.09%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

Neuronetics stock logo

Neuronetics NASDAQ:STIM

$2.16 -0.06 (-2.70%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$2.19 +0.03 (+1.34%)
As of 10/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas